According to the American Cancer Society, one in eight men will receive a prostate cancer diagnosis in his lifetime and about one in 40 will die as a result. A Keck Medicine of USC research team has now developed an innovative treatment for prostate cancer, known as synthetic immune receptor T-cell (SIR-T) therapy. The new technology was adapted from chimeric antigen receptor (CAR T-cell) therapy, which has been proven effective for several types of blood cancer.

Principal investigator Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for Blood Diseases in the Department of Medicine, Bloom Family Chair in Lymphoma Research and director of Blood and Marrow Transplant and Cell Therapy at the Keck School, has been selected to receive a $5.8 million award from the California Institute for Regenerative Medicine (CIRM) to begin conducting preclinical studies of SIR-T therapy.

To continue reading this story, click here.